Oruka Therapeutics, Inc. (ORKA) - Total Liabilities
Based on the latest financial reports, Oruka Therapeutics, Inc. (ORKA) has total liabilities worth $22.46 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Oruka Therapeutics, Inc. - Total Liabilities Trend (2005–2024)
This chart illustrates how Oruka Therapeutics, Inc.'s total liabilities have evolved over time, based on quarterly financial data. See ORKA working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Oruka Therapeutics, Inc. Competitors by Total Liabilities
The table below lists competitors of Oruka Therapeutics, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sylvamo Corp
NYSE:SLVM
|
USA | $1.80 Billion |
|
Solvac S.A.
BR:SOLV
|
Belgium | €215.41 Million |
|
Kernel Holding SA
WAR:KER
|
Poland | zł1.19 Billion |
|
Nanfang Pump Industry
SHE:300145
|
China | CN¥4.97 Billion |
|
Sixth Street Specialty Lending Inc
NYSE:TSLX
|
USA | $1.89 Billion |
|
Purecycle Technologies Holdings Corp
NASDAQ:PCT
|
USA | $878.58 Million |
|
Richelieu Hardware Ltd.
TO:RCH
|
Canada | CA$487.82 Million |
|
CPT Technology Group Co Ltd
SHE:000536
|
China | CN¥4.62 Billion |
Liability Composition Analysis (2005–2024)
This chart breaks down Oruka Therapeutics, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ORKA company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 16.94 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Oruka Therapeutics, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Oruka Therapeutics, Inc. (2005–2024)
The table below shows the annual total liabilities of Oruka Therapeutics, Inc. from 2005 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $13.80 Million | +1540.67% |
| 2023-12-31 | $841.00K | -40.44% |
| 2022-12-31 | $1.41 Million | -63.62% |
| 2021-12-31 | $3.88 Million | -0.69% |
| 2020-12-31 | $3.91 Million | +322.03% |
| 2019-12-31 | $926.00K | +16.77% |
| 2018-12-31 | $793.00K | -62.06% |
| 2017-12-31 | $2.09 Million | -14.17% |
| 2016-12-31 | $2.44 Million | +61.90% |
| 2015-12-31 | $1.50 Million | +8.12% |
| 2014-12-31 | $1.39 Million | -7.45% |
| 2013-12-31 | $1.50 Million | +392.79% |
| 2012-12-31 | $305.00K | -60.39% |
| 2011-12-31 | $770.00K | -44.40% |
| 2010-12-31 | $1.39 Million | -29.34% |
| 2009-12-31 | $1.96 Million | -88.04% |
| 2008-12-31 | $16.39 Million | -69.09% |
| 2007-12-31 | $53.02 Million | -53.72% |
| 2006-12-31 | $114.56 Million | +123.40% |
| 2005-12-31 | $51.28 Million | -- |
About Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 1 trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-1… Read more